

January 7, 1964

AIR MAIL
SPECIAL DELIVERY

Jonathan Cole, M. D.
National Bank Building
6917 Arlington Road
Bethesda, Maryland

Dear Dr. Cole:

Prior to submitting NIMI application 08597-01, "Antagonists to Anticholinergic Psychotomimetics, we met with representatives of Monsanto Chemical Company regarding our use of compounds p-phenyl mandelic acid, 2-phenanthryl glycolic acid, 3-phenanthryl glycolic acid, and phenoxymandelic acid in clinical trials. The enclosed letter was received accompanied by the verbal assurance that they (Monsanto) would continue to support the studies.

The FDA sponsorship for these compounds will be by Monsanto, U.S.A., or the Institute.

I trust this is helpful.

Sincerely yours,

Max Fink, M. D.
Executive Director

MF:mlg
Enc. 1